(RTTNews) - Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration ...
Sanofi (NASDAQ:SNY) Q3 2024 Earnings Call Transcript ... With sales of a EUR172 million ALTUVIIIO further established its ...
With sales of a EUR172 million ALTUVIIIO further established its position ... This transaction marks an important strategic step for Sanofi to become a pure-play and science-focused biopharma ...
SNY posts strong third-quarter results, beating estimates for both earnings and sales. Shares rise in pre-market.
Among Sanofi’s rare disease drugs, new rare blood disorder drug Altuviiio, a once-weekly new class of factor VIII therapy for hemophilia A, recorded sales of €172 million in the third quarter ...
Sanofi (NASDAQ:SNY) shares gained on Friday after the French pharma giant exceeded analysts' estimates with its Q3 thanks mainly to earlier-than-anticipated vaccine sales and a 22% YoY rise in ...
Sanofi confirmed its full-year sales target for Dupixent of roughly 13 billion euros. Elsewhere, new pharma launches grew 67.1% to 727 million euros ($787), with hemophilia med Altuviiio ...
Also Read: FDA Approves Regeneron/Sanofi’s Blockbuster Dupixent For Smoker’s Lung Disease New pharma launches increased 67.1% to 727 million euros, led by Altuviiio (hemophilia drug ...
Agomab Therapeutics is benefiting from Sanofi’s push to become an immunology powerhouse.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback